Pharmion - Best Pharma Stocks of 2007

Company: Pharmion
Starting stock price: $26.7
Ending stock price: $62.68
Percent Change: 135%

Details: Pnarmion acquires, develops and commercializes hematology and oncology products. In November 2007, Celgene bought Pharmion for $2.9 billion--11 times Pharmion's annual revenue and a 46 percent premium for its shares. Pharmion sells Vidaza and Thalomid and is working on a late-stage therapy for small-cell lung cancer and a mid-stage oncology drug MGCD0103.

More News:
Celgene goes global with $2.9B Pharmion buyout. Report 
Pharmion nets cancer therapy in Cabrellis buyout. Report
Pharmion signs $270M licensing deal for GPC's satraplatin. Report

Pharmion - Best Pharma Stocks of 2007

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.